Daiichi Sankyo Launches Tarlige® Tablets for Pain Treatment in Japan

Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) today announced the launch of Tarlige^® Tablets 2.5 mg, 5 mg, 10 mg, 15 mg (generic name: mirogabalin besilate; hereafter, the drug) for the treatment of pain in Japan.

This drug, an α₂δ ligand^*1 , created by Daiichi Sankyo, was approved for marketing in Japan in January 2019 on the basis of the results of phase 3 clinical trials conducted in Asia including Japan in patients with diabetic peripheral neuropathic pain (DPNP) ^*2 and postherpetic neuralgia (PHN) ^*3, for the indication of peripheral neuropathic pain (PNP) ^*4.

Daiichi Sankyo expects the drug to benefit patients in Japan by providing a new therapeutic option for the treatment of peripheral neuropathic pain.

https://www.marketscreener.com/DAIICHI-SANKYO-COMPANY-L-6498062/news/Daiichi-Sankyo-Launches-ldquo-Tarlige-Tablets-rdquo-for-Pain-Treatment-in-Japan-28421941/